The least-psychedelic president in history supports psychedelic research more than any of his predecessors

An executive order signed by Donald Trump accelerates research and approvals for psychedelic drugs aimed at serious mental illness, including ibogaine compounds. The policy push is presented as coming from a coalition around Trump that blends mainstream and countercultural influence: Joe Rogan, an ibogaine advocate, RFK Jr., and federal health leadership. The order also targets faster pathways for clinical progress for patients whose conditions persist after standard therapy, with mentions of ibogaine trials that require treatment outside the US for now. The piece frames the moment as a milestone in shifting US drug policy away from the long era of the drug war, tying it to broader public normalization of drug use and reforms like marijuana rescheduling efforts.